RxDoctor Payments Data

Shadi Milani-Nejad, DO

Neurology · Riverside, CANPI 1780048769

Payments from drug & device makers

$3,497in general payments, 2019–2025

Across 78 payments — averaging $44.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$1K
  • UCB, Inc.$652
  • AstraZeneca$367
  • CSL Behring$258
  • AbbVie$237
  • Grifols USA, LLC$196
  • plus $389 from 7 others

What the payments were for

  • Consulting fees$93827%
  • Food & beverage$2,55973%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,497 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$39,993
Medicare patients
84
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5018$339,889
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$218,655
CopaxoneGlatiramer Acetate11$63,122
Aimovig AutoinjectorErenumab-Aooe13$9,235
Memantine Hcl29$2,699
Gabapentin120$1,989
Pregabalin59$1,359
Levetiracetam23$825
Carbidopa-LevodopaCarbidopa/Levodopa29$652
Donepezil Hcl37$516
Quetiapine Fumarate26$415
Lacosamide17$359
Baclofen31$282
Atorvastatin Calcium18$235
Topiramate13$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$46$339,88918 claims
CSL BehringPrivigen$258$218,65513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →